Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.40 |
| ▸ | FLT4 | P35916 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 4/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.37 |
| ▸ | EGFR | P00533 | 6/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114117 | 0.91 | KDR (0.46) | KDRFLT4FLT3CHEK1PDGFRB | |
| SCHEMBL2114389 | 0.86 | FLT3 (0.41) | KDRFLT4FLT3CHEK1PDGFRB | |
| SCHEMBL2114116 | 0.85 | LRRK2 (0.42) | KDRFLT4FLT3PRKAA2PRKAA1 | |
| SCHEMBL2118752 | 0.82 | KDR (0.46) | KDRFLT4FLT3PRKAA1CHEK1 | |
| SCHEMBL2116963 | 0.81 | PDGFRB (0.46) | KDRPRKAA2PRKAA1PDGFRBFGFR1 | |
| SCHEMBL722802 | 0.81 | ALK (0.52) | KDRFLT4FLT3PRKAA2PRKAA1 | |
| SCHEMBL399058 | 0.81 | FLT3 (0.48) | KDRFLT4FLT3PDGFRBKIT | |
| SCHEMBL2113982 | 0.80 | KDR (0.47) | KDRFLT4FLT3CHEK1PDGFRB | |
| SCHEMBL2115792 | 0.79 | NTRK1 (0.43) | KDRFLT3PDGFRBFGFR1EGFR | |
| SCHEMBL2116213 | 0.79 | FGFR1 (0.51) | KDRFLT4FLT3CHEK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | KDR 395/4885FLT4 345/4885FLT3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.